Altimmune’s Pemvidutide shows positive topline results from IMPACT Phase IIb trial
The therapy also drove additional weight loss at the higher 1.8 mg dose without plateauing and maintained a favorable tolerability profile
The therapy also drove additional weight loss at the higher 1.8 mg dose without plateauing and maintained a favorable tolerability profile
FOP is a rare genetic disorder caused by mutations in the ALK2 kinase
The MAR-Autism Test represents more than 20 years of research at the UC Davis MIND Institute by Judy Van de Water
The system is intended for some of the tiniest patients—premature infants weighing as little as two pounds
Using a combination of blood and faecal samples, the service examines key biomarkers, including hereditary genetic status
Emcure becomes the first Indian company to exclusively distribute and commercialise Poviztra, a second brand of Novo Nordisk’s Semaglutide injection for weight management
Additional investments planned to expand the site’s capacity and capabilities to support growing manufacturing programs
The approval comes with 180 days of Competitive Generic Therapy (CGT) exclusivity,
SandboxAQ will receive an upfront payment and could earn up to $200 million in milestone payments tied to preclinical, development, regulatory, and commercial achievements
The study found BIC/LEN to be statistically non-inferior to BIKTARVY, Gilead’s current standard-of-care therapy
Subscribe To Our Newsletter & Stay Updated